SYGNIS Pharma AG, a specialty pharmaceutical company, engages in the research, development, and marketing of drugs for the treatment of disorders of the central nervous system (CNS). These include stroke or various forms of dementia. AX200 AX200 is a biological molecule, developed by the company for the treatment of neurodegenerative diseases. It is being tested in a 350 patient, multinational phase II efficacy trial. AX200 is an endogenous protein. As part of the body's own protective action the production of AX200 is boosted after brain damage. AX200 displays a multimodal activity: it stops neuronal cell death in the acute phase of the disease while at the same time stimulating the regeneration of the damaged CNS through the stimulation of neurogenesis, as well as arteriogenesis and the reorganisation of neuronal networks. Significant Events The company acquired Amnestix Inc. in 2008. Its business operations focus on the development of novel therapeutics and diagnosis techniques to enhance cognitive and memory functions. History SYGNIS Pharma AG was founded in 1997.
Show more

Employee Rating

0
TypePrivate
HQHeidelberg, DE
Founded1947
Size (employees)20 (est)
Websitesygnis.com
Sygnis Pharma was founded in 1947 and is headquartered in Heidelberg, DE
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Sygnis Pharma Office Locations

Sygnis Pharma has an office in Heidelberg
Heidelberg, (HQ)
515 Im Neuenheimer Feld
Show all (1)
Report incorrect company information

Sygnis Pharma Financials and Metrics

Summary Metrics

Founding Date

1947
Report incorrect company information

Sygnis Pharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Sygnis Pharma Blogs

DGAP-DD: Expedeon AG – 06/11/2018

The post DGAP-DD: Expedeon AG – 06/11/2018 appeared first on Expedeon Investors.

Expedeon AG: Release according to Article 41 of the WpHG – 16/10/2018

The post Expedeon AG: Release according to Article 41 of the WpHG – 16/10/2018 appeared first on Expedeon Investors.

DGAP-DD: Expedeon AG – 15/10/2018

The post DGAP-DD: Expedeon AG – 15/10/2018 appeared first on Expedeon Investors.

Expedeon AG signs supply agreement with Reszon Diagnostics for proprietary colloidal gold technology

The post Expedeon AG signs supply agreement with Reszon Diagnostics for proprietary colloidal gold technology appeared first on Expedeon Investors.

DGAP-DD: Expedeon AG – 20/09/2018

The post DGAP-DD: Expedeon AG – 20/09/2018 appeared first on Expedeon Investors.

DGAP-DD: Expedeon AG – 18/09/2018

The post DGAP-DD: Expedeon AG – 18/09/2018 appeared first on Expedeon Investors.
Show more

Sygnis Pharma Company Life and Culture

Report incorrect company information

Sygnis Pharma Frequently Asked Questions

  • When was Sygnis Pharma founded?

    Sygnis Pharma was founded in 1947.

  • How many employees does Sygnis Pharma have?

    Sygnis Pharma has 20 employees.

  • Who are Sygnis Pharma competitors?

    Competitors of Sygnis Pharma include Sol-Gel Technologies, Vifor Pharma and pSivida.

  • Where is Sygnis Pharma headquarters?

    Sygnis Pharma headquarters is located at 515 Im Neuenheimer Feld, Heidelberg.

  • Where are Sygnis Pharma offices?

    Sygnis Pharma has an office in Heidelberg.

  • How many offices does Sygnis Pharma have?

    Sygnis Pharma has 1 office.